OSE Immunotherapeutics SA (OSE.PA)
EUR 5.81
(1.66%)
EUR 5.81
(1.66%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -23.26 Million EUR | -41.04% |
| 2022 | -15.68 Million EUR | -5.75% |
| 2021 | -14.65 Million EUR | 19.32% |
| 2020 | -18.71 Million EUR | -424.26% |
| 2019 | -1.24 Million EUR | -192.26% |
| 2018 | 536 Thousand EUR | 139.7% |
| 2017 | -12.5 Million EUR | -2617.83% |
| 2016 | 15.31 Million EUR | 91.36% |
| 2015 | -5.32 Million EUR | -29461.11% |
| 2014 | -18 Thousand EUR | 92.8% |
| 2013 | -250 Thousand EUR | 82.59% |
| 2012 | -1.43 Million EUR | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | 60.63 Million EUR | 0.0% |
| 2023 Q2 | -17.37 Million EUR | 0.0% |
| 2023 Q4 | -9.3 Million EUR | 0.0% |
| 2023 FY | - EUR | -41.04% |
| 2022 Q2 | -5.09 Million EUR | 0.0% |
| 2022 Q4 | -15.48 Million EUR | 0.0% |
| 2022 FY | - EUR | -5.75% |
| 2021 FY | - EUR | 19.32% |
| 2021 Q4 | -5.33 Million EUR | 0.0% |
| 2021 Q2 | -14.05 Million EUR | 0.0% |
| 2020 Q4 | -11.76 Million EUR | 0.0% |
| 2020 FY | - EUR | -424.26% |
| 2020 Q2 | -6.95 Million EUR | 0.0% |
| 2019 Q4 | -6.23 Million EUR | 0.0% |
| 2019 Q2 | 1.65 Million EUR | 0.0% |
| 2019 FY | - EUR | -192.26% |
| 2018 FY | - EUR | 139.7% |
| 2018 Q2 | 10.41 Million EUR | 0.0% |
| 2018 Q4 | -5.45 Million EUR | 0.0% |
| 2017 FY | - EUR | -2617.83% |
| 2017 Q4 | -5.25 Million EUR | 0.0% |
| 2017 Q2 | -7.25 Million EUR | 0.0% |
| 2016 FY | - EUR | 91.36% |
| 2016 Q4 | -4.7 Million EUR | 0.0% |
| 2016 Q2 | 4.24 Million EUR | 0.0% |
| 2015 FY | - EUR | -29461.11% |
| 2015 Q4 | -2.53 Million EUR | 0.0% |
| 2015 Q2 | -2.78 Million EUR | 0.0% |
| 2014 FY | - EUR | 92.8% |
| 2014 Q4 | -17 Thousand EUR | 0.0% |
| 2014 Q2 | -1000.00 EUR | 0.0% |
| 2013 Q1 | -122.5 Thousand EUR | 0.0% |
| 2013 Q2 | -1000.00 EUR | 99.18% |
| 2013 Q3 | -127.5 Thousand EUR | -12650.0% |
| 2013 FY | - EUR | 82.59% |
| 2013 Q4 | 1000.00 EUR | 100.78% |
| 2012 FY | - EUR | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| ABIONYX Pharma SA | -3.29 Million EUR | -607.173% |
| ABIVAX Société Anonyme | -133.2 Million EUR | 82.534% |
| Adocia SA | -22.73 Million EUR | -2.349% |
| Aelis Farma SA | -6.34 Million EUR | -266.567% |
| Biophytis S.A. | -13.8 Million EUR | -68.545% |
| Advicenne S.A. | -6.24 Million EUR | -272.614% |
| genOway Société anonyme | 6.35 Million EUR | 466.35% |
| IntegraGen SA | -52.5 Thousand EUR | -44213.656% |
| Medesis Pharma S.A. | -3.84 Million EUR | -505.116% |
| Neovacs S.A. | -8.44 Million EUR | -175.352% |
| NFL Biosciences SA | -4.04 Million EUR | -474.568% |
| Plant Advanced Technologies SA | 72.53 Thousand EUR | 32177.76% |
| Quantum Genomics Société Anonyme | -2.87 Million EUR | -709.68% |
| Sensorion SA | -22.31 Million EUR | -4.267% |
| Theranexus Société Anonyme | -7.38 Million EUR | -214.949% |
| TME Pharma N.V. | -5.07 Million EUR | -358.714% |
| Valbiotis SA | -6.95 Million EUR | -234.522% |
| TheraVet SA | -517.33 Thousand EUR | -4397.27% |
| Valerio Therapeutics Société anonyme | -18.91 Million EUR | -22.996% |
| DBV Technologies S.A. | -79.53 Million EUR | 70.746% |
| Genfit S.A. | -28.05 Million EUR | 17.058% |
| GeNeuro SA | -14.31 Million EUR | -62.498% |
| Innate Pharma S.A. | -7.57 Million EUR | -207.02% |
| Inventiva S.A. | -101.84 Million EUR | 77.156% |
| MaaT Pharma SA | -19.74 Million EUR | -17.862% |
| MedinCell S.A. | -20.04 Million EUR | -16.063% |
| Nanobiotix S.A. | -34.01 Million EUR | 31.609% |
| Poxel S.A. | -12.17 Million EUR | -91.034% |
| GenSight Biologics S.A. | -21.73 Million EUR | -7.069% |
| Transgene SA | -27.02 Million EUR | 13.906% |
| Valneva SE | -64.51 Million EUR | 63.938% |